BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹731.70
- Market cap
- ₹11,517 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.5×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other other announcement announcements
All →Sealmatic India Other Announcement
Sealmatic India filed its half-yearly shareholding pattern for the period ended September 30, 2026. Promoter and promoter group hold about 72% of the equity.
Bench Mark Infotech Services Other Announcement
Bench Mark Infotech appointed EquiBridgeX Advisors as its investor and public relations agency from 31 October 2026. The appointment is routine with no financial impact.
Concord Enviro Systems Other Announcement
Concord Enviro Systems filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoters hold about 51.4%, and the filing is routine compliance disclosure.
Arman Holdings Other Announcement
Arman Holdings filed its quarterly shareholding pattern for the quarter ended September 30, 2026. The filing reports no corporate event; total shares outstanding are 52,10,500.
Taparia Tools Other Announcement
Taparia Tools filed its quarterly shareholding pattern for the period ended September 30, 2026. Promoter and promoter group hold about 71.5%, with no transaction disclosed.
Refex Industries Other Announcement
Refex Industries' quarterly shareholding pattern as of 30 September 2026 shows promoter holdings of about 56.6% and total public shareholding details. The filing reports no promoter transaction or change in control.